Enrolment Concludes for Inflammasome’s K8 Phase II Trial for GA

Enrolment concludes for Inflammasome’s K8 Phase II trial for GA

Inflammasome Therapeutics has completed subject enrolment for its multicentre Phase II trial of K8, a dual inflammasome inhibitor, aimed at treating geographic atrophy (GA).The post Enrolment concludes for Inflammasome’s K8 Phase II trial for GA appeared first on Clinical Trials Arena.

Inflammasome Therapeutics Completes Enrollment of Multicenter Phase 2 Dose-Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy

Inflammasome Therapeutics, a private, clinical-stage biotech company developing dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative diseases, announced completion of enrollment of a multicenter phase 2 dose-ranging trial (NCT06164587) for its dual inflammasome inhibitor, K8, for geographic atrophy (GA). Thirty patients with bilateral GA were recruited at nine centers throughout the Unites States. In this 6-month trial, pa…